NEW YORK, June 30 (GenomeWeb News) - Tm Bioscience has signed a five-year, $7.5 million agreement to supply InterGenetics with custom Tag-It reagents for its OncoVue breast cancer-risk test, the companies said today.
"With a potential market of over 30 million tests, growing at 2 million tests per year in the US alone, we needed to select a production technology which was scalable for very high throughput," Craig Shimasaki, president and CEO of Oklahoma City, Okla.-based InterGenetics, said in the statement. "Our OncoVue breast cancer risk test was actually designed and developed using the Tag-It universal array platform."
Tm said it plans to begin supplying products to InterGenetics in the second half of 2005. As InterGenetics completes clinical validation of additional genetic markers for ovarian and other cancers, "we anticipate expanding our agreement to include these new cancer risk assessment products," Greg Hines, president and CEO of Tm Bioscience, said in the statement.
The American Cancer Society estimates approximately 211,000 women in the